![Jonathan Hopper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Hopper
Directeur Technique/Scientifique/R&D chez
VERICEL CORPORATION
Fortune : 3 M $ au 30/09/2026
Profil
Jonathan Mark Hopper is currently Chief Medical Officer at Vericel Corp.
since 2018.
Formerly, Dr. Hopper was Vice President-Global Medical Director at Stryker Corp.
from 2010 to 2014, Medical Director at Ferring Pharmaceuticals, Inc. from 2017 to 2018, Chief Medical Officer at Osiris Therapeutics, Inc. from 2014 to 2016, Senior Medical Officer at the United Kingdom Department of Health & Social Care, and Vice President-Medical Affairs at Convatec, Inc. from 2006 to 2010.
Education includes an MBA from Keele University in 2003 and an undergraduate degree from the University of Birmingham Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERICEL CORPORATION 0,15 % | 26/06/2026 | 75 753 ( 0,15 % ) | 3 M $ | 30/09/2026 |
Postes actifs de Jonathan Hopper
| Sociétés | Poste | Début |
|---|---|---|
| VERICEL CORPORATION | Directeur Technique/Scientifique/R&D | 20/08/2018 |
Anciens postes connus de Jonathan Hopper
| Sociétés | Poste | Fin |
|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets fertility and endocrinology products | Directeur Technique/Scientifique/R&D | 01/08/2018 |
| OSIRIS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 12/04/2016 |
| STRYKER CORPORATION | Directeur Technique/Scientifique/R&D | 01/11/2014 |
ConvaTec, Inc.
 ConvaTec, Inc. Medical SpecialtiesHealth Technology Develops and manufactures products for the ostomy management, advanced chronic and acute wound care and continence care services | Directeur Technique/Scientifique/R&D | 01/08/2010 |
United Kingdom Department of Health & Social Care
 United Kingdom Department of Health & Social Care General GovernmentGovernment Functions as a health and social care department | Corporate Officer/Principal | - |
Formation de Jonathan Hopper
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
76
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Stryker Corp.
 Stryker Corp. Medical SpecialtiesHealth Technology Manufactures and markets reconstructive, medical and surgical, and neurotechnology and spine products | Health Technology |
Vericel Corp.
 Vericel Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures and markets two advanced cell therapy products for sports medicine and severe burn care | Health Technology |
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Researches and develops therapeutic products for the regeneration of human connective tissues | Health Technology |
United Kingdom Department of Health & Social Care
United Kingdom Department of Health & Social Care General GovernmentGovernment Functions as a health and social care department | Government |
ConvaTec, Inc.
ConvaTec, Inc. Medical SpecialtiesHealth Technology Develops and manufactures products for the ostomy management, advanced chronic and acute wound care and continence care services | Health Technology |
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets fertility and endocrinology products | Health Technology |
Keele University
 Keele University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Birmingham Medical School
 University of Birmingham Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
